Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma
- PMID: 10554016
Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma
Abstract
Recently, cell-free EBV DNA has been detected in the plasma and serum of patients with nasopharyngeal carcinoma (NPC). We studied the relationship between plasma/serum EBV DNA and tumor recurrence. Using real-time quantitative PCR, the median plasma EBV DNA concentration in 10 patients with tumor recurrence was determined to be 32,350 copies/ml, whereas that in 15 patients in continuous remission for a mean period of 2 years was 0 copy/ml. Longitudinal follow-up of 17 NPC patients revealed 6 individuals with tumor recurrence and 11 patients who remained in remission. Significant elevations in serum EBV DNA, sometimes up to 6 months before detectable clinical deterioration, were observed in the patients who subsequently developed tumor recurrence. Continuously low or undetectable levels of serum EBV DNA were observed in the patients who remained in remission. These results suggest that plasma/serum cell-free EBV DNA may be a valuable tool for the monitoring of NPC patients for the early detection of tumor recurrence.
Similar articles
-
Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.Cancer. 2004 Mar 15;100(6):1162-70. doi: 10.1002/cncr.20099. Cancer. 2004. PMID: 15022282
-
[Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].Ai Zheng. 2003 Jun;22(6):645-8. Ai Zheng. 2003. PMID: 12948418 Chinese.
-
[Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].Ai Zheng. 2003 Mar;22(3):302-6. Ai Zheng. 2003. PMID: 12654192 Chinese.
-
Serum/plasma viral DNA: mechanisms and diagnostic applications to nasopharyngeal and cervical carcinoma.Ann N Y Acad Sci. 2001 Sep;945:59-67. Ann N Y Acad Sci. 2001. PMID: 11708495 Review.
-
Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma.Oral Oncol. 2014 Jun;50(6):527-38. doi: 10.1016/j.oraloncology.2013.12.011. Epub 2014 Jan 15. Oral Oncol. 2014. PMID: 24440146 Review.
Cited by
-
Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.PLoS One. 2015 Apr 8;10(4):e0122756. doi: 10.1371/journal.pone.0122756. eCollection 2015. PLoS One. 2015. PMID: 25853677 Free PMC article.
-
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.Lancet Oncol. 2012 Feb;13(2):172-80. doi: 10.1016/S1470-2045(11)70303-5. Epub 2011 Dec 15. Lancet Oncol. 2012. PMID: 22178121 Free PMC article. Clinical Trial.
-
Risk stratification for nasopharyngeal carcinoma: a real-world study based on locoregional extension patterns and Epstein-Barr virus DNA load.Ther Adv Med Oncol. 2020 Jun 12;12:1758835920932052. doi: 10.1177/1758835920932052. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32587634 Free PMC article.
-
Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.J Clin Pathol. 2006 May;59(5):537-41. doi: 10.1136/jcp.2005.030544. Epub 2006 Feb 17. J Clin Pathol. 2006. PMID: 16489178 Free PMC article.
-
Recurrence risk stratification based on Epstein-Barr virus DNA to identify enlarged retropharyngeal lymph nodes of nasopharyngeal carcinoma: A model-histopathologic correlation study.Front Med (Lausanne). 2022 Dec 1;9:996127. doi: 10.3389/fmed.2022.996127. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36530897 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources